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The urine excretion of L-carnitine (LC), acetyl-L-carnitine (ALC) and propionyl-Lcarnitine (PLC) and 
their relations with the antioxidant activities are presently unknown. Liquid L-carnitine (2.0 g) was 
administered orally as a single dose in 12 healthy subjects. Urine concentrations of LC, ALC and PLC were 
detected by HPLC. Superoxide dismutase (SOD), total antioxidative capacity (T-AOC), malondialdehyde 
(MDA) and nitrogen monoxidum (NO) activities were measured by spectrophotometric methods. The 
0~2 h, 2~4 h, 4~8 h, 8~12 h, 12~24 h excretion of LC was 53.13±31.36 μmol, 166.93±76.87 μmol, 
219.92±76.30 μmol, 100.48±23.89 μmol, 72.07±25.77 μmol, respectively. The excretion of ALC was 
29.70±14.43 μmol, 80.59±32.70 μmol, 109.85±49.21 μmol, 58.65±18.55 μmol, and 80.43±35.44 μmol, 
respectively. The urine concentration of PLC was 6.63±4.50 μmol, 15.33±12.59 μmol, 15.46±6.26 μmol, 
13.41±11.66 μmol and 9.67±7.92 μmol, respectively. The accumulated excretion rate of LC was 6.1% 
within 24h after its administration. There was also an increase in urine concentrations of SOD and T-AOC, 
and a decrease in NO and MDA. A positive correlation was found between urine concentrations of LC 
and SOD (r = 0.8277) or T-AOC (r = 0.9547), and a negative correlation was found between urine LC 
excretions and NO (r = -0.8575) or MDA (r = 0.7085). In conclusion, a single oral LC administration 
let to a gradual increase in urine L-carnitine excretion which was associated with an increase in urine 
antioxidant enzymes and the total antioxidant capacities. These data may be useful in designing therapeutic 
regimens of LC or its analogues in the future.
Uniterms: L-carnitine/antioxidant activity. Acetyl-L-carnitine/antioxidant activity. Propionyl-Lcarnitine/
antioxidant activity. Antioxidants. Urine excretion/analysis.
A excreção urinária de L-carnitina (LC), acetil-L-carnitina (ALC) e propionil-L-carnitine (PLC) 
e as suas relações com as atividades antioxidantes são presentemente desconhecidos. Líquido de 
L-carnitina (2,0 g) foi administrada por via oral como uma dose única em 12 indivíduos saudáveis. 
As concentrações urinárias de LC, PLC e ALC foram detectados por HPLC. Atividades superóxido 
dismutase (SOD), a capacidade antioxidante total (T-AOC), malondialdeído (MDA) e óxido nítrico 
(NO) foram medidas por métodos espectrofotométricos. O 0~2 h, 2~4 h, 4~8 h, 8~12 h, 12~24 h 
excreção de LC foi 53,13±31.36 μmol, 166,93±76.87 μmol, 219,92±76.30 μmol, 100,48±23.89 μmol, 
72,07±25.77 μmol, respectivamente. A excreção de ALC foi 29,70±14.43 μmol, 80,59±32.70 μmol, 
109,85±49.21  μmol,  58,65±18.55  μmol,  e  80,43±35.44  μmol,  respectivamente. A  concentração 
de  urina  de  PLC  foi  6,63±4.50  μmol,  15,33±12.59  μmol,  15,46±6.26  μmol,  13,41±11.66  μmol  e 
9,67±7.92 μmol, respectivamente. A taxa de excreção acumulada de LC foi de 6,1% 24 horas após sua 
administração. Houve também um aumento nas concentrações de urina de SOD e T-COA e diminuição 
de NO e de MDA. Correlação positiva foi encontrada entre as concentrações de urina de LC e SOD 
(r = 0,8277) ou T-AOC (r = 0,9547) e correlação negativa entre a excreção de LC e NO (r = -0,8575) 
ou MDA (r = 0,7085). Em conclusão, a administração oral única de LC leva ao aumento gradual na 
excreção urinária de L-carnitina, que foi associada com o aumento das enzimas antioxidantes na urina 
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e as capacidades antioxidantes totais. Estes dados podem ser úteis no futuro para o planejamento de 
esquemas terapêuticos de LC ou os seus análogos, no futuro.
Unitermos: L-carnitina/atividade antioxidante. Acetil-L-carnitina/atividade antioxidante. Antioxidantes. 
Urina/excreção/análise.
INTRODUCTION
L-carnitine (3-hydroxy-4-N-trimethylammonium 
butyrate, LC) is an endogenous compound which has sev-
eral physiological functions. LC is involved in the transfer 
of long-chain fatty acids across the inner matrix membrane 
of mitochondria (Mancinelli et al., 2007). It also regulates 
acetyl storage and transfer in mitochondria, cells, and 
between organs, and the transport of potentially toxic, 
activated acids out of mitochondria (Bellinghieri et al., 
2003). LC is believed to be important for acting as an osmo 
protectant in organs such as the kidney, and as a general 
cell membrane stabilizer (Lahjouji et al., 2004; Biolo et 
al., 2008). LC homeostasis is maintained by a modest bio-
synthesis in the liver and kidney, absorption from dietary 
sources (eg, meat and dairy products), and efficient renal 
tubular reabsorption from glomerular filtrate (Rebouche, 
Seim 1998). Short-chain carnitine esters, including acetyl-
Lcarnitine (ALC) and propionyl-L-carnitine (PLC), are 
produced by esterification of the hydroxyl group of LC. 
LC, ALC and PLC form components of the endogenous 
carnitine pools in humans and experimental animals (Man-
cinelli et al., 2000). There is a reciprocal transformation 
among the three carnitine analogues (LC, ALC and PLC) 
(Cao et al., 2009). Acetylation of L-carnitine and the 
transformation to ALC or PLC can take place during the 
absorption process (Gross, Henderson, 1984; Gudjonsson 
et al. 1985).
LC is administered clinically for the treatment of 
primary and secondary carnitine deficiency syndromes. 
Available biochemical and clinical information provides 
a strong rationale for carnitine supplementation to patients 
on hemodialysis (Guarnieri et al., 2007). Bioavailability 
of dietary LC in individuals adapted to low-carnitine is be-
tween 54% to 72% (Rebouche, Chenard, 1991). However, 
the bioavailability of L-carnitine from oral supplements 
was lower than dietary LC, ranging from 14%-18% of the 
total dose (Rebouche, 2004). ALC supplementation has 
been reported to reduce the progression of Alzheimer’s 
disease (Gavrilova et al., 2011; Pettegrew, McClure 2002). 
Patients with intermittent claudication exhibited improved 
walking capacity after the administration of PLC (Brevetti 
et al., 1995).
Apart from the physiological roles in intermedi-
ary metabolism, LC has also been found to possess 
antioxidant properties, such as prevention of DNA 
damages and increase of non-enzymatic and enzymatic 
antioxidant levels (Ribas et al., 2012; Derin et al., 2004). 
LC also raises the activities of blood antioxidant enzymes 
and total antioxidant capacity in a concentration-depen-
dent manner (Cao et al., 2011). However, there has been 
limited information about the relationships between the 
urine concentrations of LC and and anti-oxidation in in 
healthy humans. The aim of this study was to investi-
gate the urine concentration of LC, ALC and PLC after 
a single oral administration of L-carnitine solution in 
healthy volunteers, and to evaluate their urine antioxidant 
status through the measurement of superoxide dismutase 
(SOD), total antioxidative capacity (T-AOC), nitrogen 
monoxidum (NO), and malondialdehyde (MDA) activi-
ties in the urine.
MATERIALS AND METHODS
Drugs, reagents and apparatus
Standard preparations of L-carnitine (purity 99%, 
batch No. 060708, 10 ml: 1 g) were obtained from 
Northeast Pharmaceutical Group Co., China. 1-Ethyl-
3-(3-dimethyllaminopropyl) carbodiimide hydrochlo-
ride (EDC-HCL) and 1-aminoanthracen (1-AA) were 
supplied by Sigma. Acetonitrile (HPLC grade reagent) 
was purchased from Honeywell international INC. Other 
reagents (hydrochloric acid, acetone, ammonium acetate, 
aether, glacial acetic acid, chloroform) were of analyti-
cal grade.
Study participants
This study was approved by the Institutional Re-
view Board of Qingdao University. Informed written 
consent was obtained from all participants. Healthy vol-
unteers were invited from the staff working at the hospital 
clinics and those who attended the clinics for annual 
health check-ups. All subjects were free from pulmonary, 
neurologic, hematologic and gastrointestinal diseases. 
None of the participants were past or current smokers. A 
thorough physical examination was performed, and the 
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following laboratory tests were conducted: blood cell 
counts, biochemistry profile, liver and renal function 
tests and electrocardiogram. The volunteers were not 
permitted to consume alcohol for 72 h before or during 
the study, and were asked to abstain from any medica-
tions for at least 1 week before and during the study. 
All subjects were prescribed a similar diet commencing 
two weeks before the study. In the prescribed diet there 
were green vegetables, rice, 50 g/day of cooked chicken 
meat, but no milk, other forms of meat or diary product 
such as cheeses.
Study design
A single dose of LC (2.0 g in 200 mL warm water) 
was administered orally to all participants. The Urine was 
collected just before (0 h) and at 0~2 h, 2~4  h, 4~8 h, 
8~12 h, and 12~24 h after the oral administration of LC. 
The urine volume at each time point was recorded. Five 
ml of the urine was transferred into a polypropylene tube 
and kept at -20 oC for analysis.
Chromatographic conditions and extraction 
procedure
The analytes were precolumn derivatived with l-
aminoanthracene (1-AA). The fluorescent derivatives were 
separated on a Hypersil C18 column, and the mobile phase 
consisted of acetonitrile-0.1 mol.L-1 ammonium acetate 
(34:66), the flow rate was 1.0 mL.min-1. The derivatives 
were monitored with a fluorimetric detector set at 248 nm 
excitation wavelength and 418 nm emission wavelength. 
We have previously reported the extraction procedure and 
validation of the methodologies (Cao et al., 2009, 2011).
Determination of urine excretion and 
accumulated excretion rate
The urine excretion was a summation of excretion 
through multiplying the concentration and volume in 
0~2 h, 2~4 h, 4~8 h, 8~12 h, 12~24 h, respectively. The 
accumulated excretion rate of LC was calculated by divid-
ing accumulated excretion of LC with the oral dose (2.0 g).
Determination of antioxidant index
The urine samples were subjected to the measure-
ment of SOD, T-AOC, NO and MDA by spectrophoto-
metric methods according to the procedures provided by 
the assay kits (purchased from Nanjing Jiancheng Bioen-
gineering Institute, Nanjing, China).
Statistical analysis
Data are expressed as means ± SD. SPSS15.1 soft-
ware was used for data analysis. Numerical data were 
analyzed with one-way ANOVA. Categorical data were 
analyzed with Chi-square test. Pearson correlation was 
used to analyze the correlations between LC and the con-
centrations of SOD or T-AOC, NO or MDA. P<0.05 was 
considered statistically significant.
RESULTS
Urine excretion of LC, ALC, PLC and accumulated 
excretion rate of LC
The 0~2 h, 2~4 h, 4~8 h, 8~12 h, 12~24 h urine ex-
cretion of LC was 53.13±31.36 μmol, 166.93±76.87 μmol, 
219 .92±76 .30  μmol ,  100 .48±23 .89  μmol  and 
72.07±25.77 μmol, respectively. The excretion of 
ALC was 29.70±14.43 μmol, 80.59±32.70 μmol, 
109 . 85±49 . 21  μmo l ,  58 . 65±18 . 55μmo l ,  a n d 
80.43±35.44 μmol, respectively, and the urine excre-
tion of PLC was 6.63±4.50 μmol, 15.33±12.59 μmol, 
15.46±6.26 μmol, 13.41±11.66 μmol, and 9.67±7.92 μmol, 
respectively (Figure 1). The accumulated urine excretion 
rate of LC was 6.1% within 24 h after its administration.
Urinary antioxidant status
As shown in Table I, after single oral administration 
of LC, the excretion of LC increased gradually from 0~2 h 
to 4~8 h, and reached the peak at 4~8 h. The antioxidant 
index of SOD and T-AOC had the same transmutation as 
the excretion, however NO and MDA had a conversely 
changing tendency. The mean concentrations of SOD 
and T-AOC in 2~4 h,4~8 h were higher than in 0~2 h (P 
FIGURE 1 - The urinary excretion of LC, ALC, PLC and the 
urinary excretion rate of LC after single oral administration.
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<0.05), however the mean concentrations of NO and MDA 
in 2~4 h, 4~8 h and 8~12 h were lower than in 0~2 h (P 
<0.05).
Correlation analysis
A positive correlation was found between excretion 
of LC and urine concentrations of SOD (r = 0.8277) or 
T-AOC (r = 0.9547). A negative correlation was found 
between LC excretion and NO (r = -0.8575) or MDA 
(r = -0.7085).
DISCUSSION
The present study found that urine excretion of LC, 
ALC, and PLC started within one hour and reached its 
peak between 4-8 h after a single oral administration in 
healthy subjects. This study also demonstrated a gradual 
increase in the urine antioxidant index of SOD and T-AOC 
within the first 8h of LC administration. Furthermore, a 
positive correlation was found between urine LC excretion 
and urine concentrations of SOD or T-AOC.
In 1991, Rebouche (1991) published a pivotal paper 
that provided a quantitative estimation of the fate of an 
oral tracer dose of L-[methyl-3H]-carnitine in five men 
who were receiving a high-carnitine diet and L-carnitine 
supplementation. It was found that the absorption of oral 
L-[3H]-carnitine was slow and incomplete, with tmax val-
ues of 2–4.5 hours. This suggests a prolonged retention of 
that fraction of the dose that had been incorporated into 
the body’s carnitine pool. In their study, only 6.3% of the 
oral LC dose was recovered unchanged in the urine, with 
a further 34% recovered in urine as metabolites, mostly 
[3H]-trimethylamine-N-oxide (Rebouche, 1991). About 
22% of the dose was recovered in feces, mostly as labeled 
γ-butyrobetaine (Rebouche, 1991). In our study, after a 
single dose of LC, the urine excretion of LC increased 
gradually from 0~2 h to 4~8 h, and reached the peak at 
4~8 h. The excretion rate of L-carnitine was only 6.1%, 
which was consistent with Rebouche’s report (Rebouche, 
1991). The excretion of ALC and PLC also increased and 
reached the peak within 8h following LC administration, 
which suggests that acetylation of LC and the transforma-
tion to ALC or PLC can take place in vivo. One notable 
variation was that the excretion of ALC between 12-24 h 
was greater than that between 8-12 h (80.4 vs 58.7 μmol). 
The reason for this is unclear, but whether there is a second 
phase of urinary ALC excretion 12 h after LC administra-
tion requires further investigation.
In kidneys, LC decreased the severity of renal corti-
cal proximal tubular necrosis and improved renal function 
in rats with gentamicin-induced or doxorubicin-induced 
renal injury (Boonsanit et al., 2006; Kopple et al., 2002). 
LC reversed the increases in blood BUN and creatinine 
following the doxorubicin or gentamicin caused renal 
injuries. LC has been shown to reduce the severity of 
glycerol-induced myoglobinuric kidney damages, indicat-
ing that LC may be a beneficial agent in the prevention 
and treatment of glycerol-induced myoglobinuric acute 
renal failure (Ustundag et al., 2009). The mechanisms of 
the renal protective effect of LC are not entirely clear. In 
previous studies, LC has been shown to have antioxidant 
effects against oxidative damage in different organs or tis-
sues, including the kidney (Aydogdu et al., 2006; Chang et 
al., 2002). It has been demonstrated that LC administration 
inhibits both serum and kidney tissue MDA formation in 
response to renal ischaemia–reperfusion injury (Ergün 
et al., 2001). Carnitine supplementation has been found 
to enhance the activities of antioxidant enzymes, such as 
SOD, CAT and GPx, and decrease the MDA concentration 
in kidney tissues of 24-month-old rats (Kalaiselvi, Pan-
neerselvam, 1998). The direct antioxidant effects of LC 
might contribute to attenuation of oxidative stress in kid-
ney tissues (Sener et al., 2004). Antioxidant effects of car-
nitine were also shown in vitro studies, and in patients on 
hemodialysis (Guarnieri et al., 2007; Pertosa et al., 2005). 
TABLE I - The urine excretion of L-carnitine and the antioxidative parameters
Time (h) Excretion (μmol) SOD U (mL-1) T-AOC (U mL-1) NO (μmol L-1) MDA (μmol mL-1)
0 0.94±0.82 17.49±5.69 28.67±7.08 3.69±1.98 3.05±1.99
0~2 53.13±31.36 22.53±10.01 40.13±16.70 2.12±0.68 2.86±1.62
2~4 166.93±76.87** 39.70±10.46* 64.92±22.86* 0.40±0.10* 0.16±0.10*
4~8 219.92±76.30** 33.31±10.95* 64.12±30.77* 0.72±0.39* 0.65±0.42*
8~12 100.48±23.89** 26.19±12.18 46.90±22.84 1.05±0.79* 0.67±0.62*
12~24 72.07±25.77* 24.08±8.37 43.44±15.28 1.70±0.88 1.26±1.09
SOD, superoxide dismutase activity; T-AOC, total antioxidative capacity; NO, nitrogen monoxidum; MDA, malondialdehyde. 
*P<0.05 and **P<0.01, compared with 0~2h.
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These effects could in turn reduce oxidative stress–induced 
inflammation and insulin resistance (Evans et al., 2003). 
We have also previously reported that aadministration of 
liquid LC could raise the activities of plasma antioxidant 
enzymes and total antioxidant capacity in a concentration-
dependent manner in healthy human volunteers (Cao et 
al., 2011). In the present study, the transmutation of urine 
SOD, T-AOC, NO, and MDA provides further evidence to 
confirm that LC could increase the antioxidant activities 
in healthy subjects.
There have been some studies to compare the effect 
of LC with other antioxidant biomolecules. In hypoxia-
induced lipid peroxidation in the brain during postnatal 
ontogenesis, the protective effect of LC is comparable 
with the effect of tocopherol, well-known reactive spe-
cies scavenger (Rauchová et al., 2012). In the obstructed 
kidney of rats subjected to 24-hr of unilateral ureteral 
obstruction (UUO), LC reduced oxidative stress and 
suppressed energy metabolism, while α-tocopherol only 
prevented redox imbalance (Moosavi SM et al., 2011). The 
effect of LC on superoxide anion radical scavenging and 
hydrogen peroxide scavenging seems comparable with 
alpha-tocopherol and trolox (Gülçin, 2006). L-carnitine 
seems to have more protective effects than selenium on 
the electromagnetic radiation-induced blood toxicity by 
inhibiting free radical supporting antioxidant redox system 
(Gumral et al., 2009).
In this study, there was a moderate increase in uri-
nary SOD within 2-8 hr of LC administration. The reasons 
for this SOD increase are unclear. SOD is a large molecule 
which is usually reabsorbed in the kidney and urine SOD 
should be negligible in healthy subjects. Whether LC 
increased kidney injury leading to higher SOD releaser 
requires further investigation.
In summary, this study in healthy Chinese subjects 
has demonstrated that following oral administration of 
LC, there was a gradual increase in the urine excretion of 
L-carnitine, ALC and PLC, with a peaking excretion oc-
curring between 4 and 8 h after the drug administration. 
This study also showed that there was an increase in the 
antioxidant activities in the urine after LC administration. 
The antioxidant activities were closely correlated with the 
urine LC excretion. These data may be useful in design-
ing therapeutic regimens of L-carnitine or its analogues 
in the future.
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